Related Experiment Video
Updated: Jun 4, 2026
06:15
Anterior High-Resolution Optical Coherence Tomography in the Diagnosis and Therapeutic Monitoring of Ocular Surface Squamous Neoplasia
Published on: August 9, 2024
Blepharitis and trichomegaly induced by cetuximab
Paulo Ricardo Criado1, Aline Angélica Porto Rocha Lima
1School of Medicine, University of Sao Paulo, Brazil. prcriado@uol.com.br
Anais Brasileiros De Dermatologia
|February 11, 2011
Summary
A patient with advanced colorectal cancer experienced severe eyelid inflammation and eyelash growth after cetuximab treatment. Further research is needed to understand the exact cause of this cetuximab-related eyelid toxicity.
Area of Science:
- Oncology
- Dermatology
- Ophthalmology
Background:
- Cetuximab is a monoclonal antibody used to treat advanced colorectal cancer.
- Eyelid toxicity is a known side effect of cetuximab therapy.
- The precise mechanisms underlying cetuximab-induced eyelid toxicity remain unclear.
Observation:
- A 41-year-old woman undergoing treatment for advanced colorectal cancer developed severe bilateral blepharitis (eyelid inflammation).
- The patient also experienced trichomegaly (abnormally thick and long eyelashes) following the second dose of cetuximab.
- These adverse effects specifically impacted the eyelid region.
Findings:
- The case report documents a severe instance of blepharitis and trichomegaly.
- The onset of these symptoms was temporally linked to cetuximab administration.
- This observation adds to the existing data on cetuximab-related ocular side effects.
Implications:
- Understanding the pathogenesis of cetuximab-related eyelid toxicity is crucial for patient management.
- This case highlights the need for vigilant monitoring of ocular side effects in patients receiving cetuximab.
- Further investigation into the biological pathways involved may lead to preventative or therapeutic strategies.
